BOLD
Boundless Bio Inc.

751
Loading...
Loading...
News
all
press releases
Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's What You Should Know
Zacks·5mo ago
News Placeholder
More News
News Placeholder
Boundless Bio Adjusts Stock Options to Incentivize Key Staff
Boundless Bio Inc. (BOLD) has shared an update. Boundless Bio, Inc. has initiated a stock option repricing for select employees and executive officers to $3.56 per share, aligning with the company's...
TipRanks Financial Blog·1y ago
News Placeholder
Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene...
Business Wire·1y ago
News Placeholder
Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene...
Business Wire·1y ago
News Placeholder
Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene...
Business Wire·1y ago
News Placeholder
Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050
Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050 Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050 PR Newswire VANCOUVER, BC, May 1, 2024 USA News Group Commentary...
PR Newswire·1y ago
News Placeholder
Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene...
Business Wire·1y ago
News Placeholder
Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene...
Business Wire·1y ago
News Placeholder
Boundless Bio Announces Pricing of Initial Public Offering
Boundless Bio, Inc. (Nasdaq: BOLD), a clinical stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable...
Business Wire·2y ago

Latest BOLD News

View

Advertisement|Remove ads.

Advertisement|Remove ads.